[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res; 2008;27:6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
  • Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans.
  • Interestingly, this neoplasm has been occasionally described in companion animals as well.
  • Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets.
  • Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium.
  • A surgical biopsy further substantiated the diagnosis.
  • After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg.
  • The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass.
  • The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carboplatin / administration & dosage. Cat Diseases / drug therapy. Dog Diseases / drug therapy. Mesothelioma / veterinary. Piroxicam / administration & dosage. Pleural Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Dogs. Drug Administration Routes. Drug Administration Schedule

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Intern Med. 1999 Nov-Dec;13(6):529-33 [10587251.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):443-9 [18365537.001]
  • [Cites] J Small Anim Pract. 2000 Aug;41(8):342-7 [11002935.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3533-44 [12177114.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):148-56 [12601280.001]
  • [Cites] Dtsch Tierarztl Wochenschr. 2003 Apr;110(4):177-8 [12756962.001]
  • [Cites] Vet Pathol. 1978 Nov;15(6):781-3 [751315.001]
  • [Cites] Nihon Juigaku Zasshi. 1982 Dec;44(6):975-9 [7182639.001]
  • [Cites] Nihon Juigaku Zasshi. 1985 Jun;47(3):511-6 [4032940.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):86-91 [3543239.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Am J Vet Res. 1990 Oct;51(10):1682-7 [2240791.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Vet Intern Med. 1991 Jul-Aug;5(4):227-31 [1658318.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Comp Pathol. 1994 Nov;111(4):453-8 [7884062.001]
  • [Cites] Nat Med. 1997 Aug;3(8):913-6 [9256285.001]
  • [Cites] J Am Vet Med Assoc. 1997 Sep 15;211(6):736-40 [9301745.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Feline Med Surg. 2005 Oct;7(5):313-6 [15914055.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10120-1 [16267039.001]
  • [Cites] J Comp Pathol. 2006 May;134(4):347-54 [16712862.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(12):2000-4 [16963313.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43 [17062690.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):201-6 [10761756.001]
  • (PMID = 18577247.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2438333
  •  go-up   go-down


2. Cerfolio RJ, Bryant AS: Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study. J Thorac Cardiovasc Surg; 2008 Feb;135(2):261-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study.
  • OBJECTIVE: Video-assisted lobectomy is an increasingly used technique to treat patients with non-small cell lung cancer but it does not usually afford lung palpation.
  • All patients underwent 64-slice helical computed tomographic scan with intravenous contrast at 5-mm intervals and had integrated 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography computed tomography 30 days or less before thoracotomy.
  • Unsuspected malignant pulmonary nodules that were palpated and removed (from a different lobe than the one resected) and that were not imaged preoperatively were defined as cancer that would have been missed by video-assisted lobectomy.
  • RESULTS: From January 2006 to February 2007, 166 patients had non-small cell lesions that were resected via thoracotomy, despite being amenable to video-assisted surgery, by one surgeon.
  • Thirty-seven (22%) patients had pulmonary nodules that probably would have been missed by video-assisted lobectomy; 14 (8.4%) of these nodules were malignant.
  • These were unsuspected M1 pulmonary lesions in 9 patients and unsuspected different types of primary non-small cell lung cancers in 5 patients.
  • Nine patients received adjuvant chemotherapy because of these unsuspected M1 nodules.
  • CONCLUSIONS: Open lobectomy that affords palpation of the rest of the lung may discover nonimaged malignant pulmonary nodules in different lobes in 8% to 9% of patients with non-small cell lung cancer despite preoperative fine-cut chest computed tomographic scan with contrast and integrated integrated 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography computed tomographic scanning.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Lymph Nodes / pathology. Palpation / methods. Thoracotomy / methods
  • [MeSH-minor] Aged. Analysis of Variance. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidental Findings. Male. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Invasiveness. Pneumonectomy / methods. Positron-Emission Tomography / methods. Probability. Prospective Studies. Survival Analysis. Thoracic Surgery, Video-Assisted / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242247.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Three of the nine resected specimens showed foci of squamous cell carcinoma in situ.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


Advertisement
4. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Among them, the most frequent is small cell carcinoma (13-17%).
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


5. Junker K: [Current morphological diagnosis of malignant lung tumors]. Pathologe; 2006 Mar;27(2):90-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current morphological diagnosis of malignant lung tumors].
  • The histological classification of lung tumors is based upon the 2004 WHO classification.
  • Small cell lung cancer (SCLC) is primarily treated by means of anti-neoplastic chemotherapy, independently of the tumor stage.
  • In resectable stages of non-small cell lung cancer (NSCLC, UICC-stages I and II), complete tumor resection is the aim.
  • Currently, great interest is focused on the identification of specific therapeutic targets, especially on the inhibition of the epidermal growth factor ruptur (EGFR).
  • Today, malignant lung tumors can also be classified by means of molecular pathology.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Gene Expression Profiling. Humans. Lung / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15203-8 [11752463.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):245-58 [12928116.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2192-205 [12687021.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5360-70 [15064725.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1193-6 [15865065.001]
  • [Cites] Pathologe. 2004 Nov;25(6):475-80 [15375632.001]
  • [Cites] Can J Public Health. 2003 Jul-Aug;94(4):292-6 [12873089.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Jul;126(7):361-8 [10929757.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3237-48 [15161676.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):98-104 [12629062.001]
  • (PMID = 16435095.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 25
  •  go-up   go-down


6. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, Yamamoto N, Kameya T: Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer; 2010 Jun;68(3):438-45
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
  • BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) shares several features with small cell lung carcinoma (SCLC).
  • While the diagnosis of LCNEC by biopsy specimens is challenging, a definitive diagnosis of this highly malignant tumor is critical in unresectable cases to determine the optimal therapeutic strategy.
  • The objective of this study was to assess the efficacy of chemotherapy for unresectable high-grade non-small cell neuroendocrine carcinoma (HNSCNEC) called by us, which likely includes most LCNECs except for combined types, and to compare the efficacy of chemotherapy for HNSCNEC, with that for extended disease SCLC (ED-SCLC).
  • We simultaneously evaluated the clinical response to the chemotherapy and survival time of the 14 HNSCNEC and 77 ED-SCLC patients.
  • RESULTS: The chemotherapy regimens in the 14 patients with unresectable HNSCNEC were platinum-based combination regimens or irinotecan or vinorelbine or docetaxel alone.
  • The chemotherapy regimens in the 77 patients with ED-SCLC were platinum-based combination regimens.
  • We assessed an objective response rate, a one-year survival rate, and median survival time as 50% (7/14), 34% and 10 months, respectively, in the 14 HNSCNEC patients, and as 53% (41/77), 48% and 12.3 months, respectively, in the 77 ED-SCLC patients.
  • CONCLUSION: The clinical efficacy of chemotherapy for unresectable HNSCNECs, including most LCNECs, is comparable to that for ED-SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Drug Therapy, Combination. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19699548.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 7673326042 / irinotecan; Q6C979R91Y / vinorelbine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Okuma Y, Hosomi Y, Kitamura K, Iguchi M, Okamura T, Fukami S, Hishima T, Shibuya M: Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy. Int J Clin Oncol; 2009 Dec;14(6):541-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy.
  • A 56-year-old male patient complaining of productive cough, hoarseness, and fatigue was found to have extensive disease of small cell lung cancer (ED-SCLC), with staging of cT4N3M1(PUL).
  • He was treated with chemotherapy.
  • While undergoing treatment with chemotherapy, he complained of a right visual disturbance, and choroidal metastasis was diagnosed.
  • Because the primary site responded well to chemotherapy alone and the visual disturbance did not worsen, the patient refused radiotherapy to the choroidal metastasis.
  • Two months after the first diagnosis of the choroidal metastasis, while he was receiving the first treatment regimen for SCLC, the visual disturbance suddenly worsened; emergent radiotherapy was started, with a total dose of 40 Gy, given as 2.0 Gy/fraction per day.
  • Within 6 months of diagnosis, the patient became blind in his right eye.
  • The patient died of septic shock related to treatment received during his third chemotherapy regimen.
  • Choroidal metastasis is very rare with extraocular malignant tumors, though it is common with intraocular malignant tumors.
  • Choroidal metastasis secondary to SCLC has a poor prognosis, but in order to maintain quality of life during the patients' remaining lifespan, aggressive treatment would appear appropriate for these patients, because SCLC is a chemo-sensitive cancer.
  • [MeSH-major] Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Small Cell Lung Carcinoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1998 Mar;46(3):263-8 [9572619.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):601-4 [11733980.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):723-6 [6022244.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):229-30 [10696136.001]
  • [Cites] Intern Med. 1999 Jul;38(7):597-601 [10435368.001]
  • [Cites] Arch Ophthalmol. 1971 Jun;85(6):673-5 [5562786.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):445-7 [12208262.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):399-403 [17397962.001]
  • [Cites] Arch Bronconeumol. 2005 Feb;41(2):99-101 [15718005.001]
  • [Cites] Am J Ophthalmol. 1983 Jun;95(6):788-93 [6859188.001]
  • [Cites] Ophthalmology. 1997 Aug;104(8):1265-76 [9261313.001]
  • (PMID = 19967493.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut; 2005 Sep;54(9):1298-308
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Pancreatic cancer remains a devastating diagnosis with only limited therapeutic options.
  • Specific inhibition of expression of target genes has become possible using small interfering (si) RNAs.
  • We therefore investigated how far siRNA specific for bcl-2 may serve as a therapeutic option for pancreatic cancer in vitro and in vivo.
  • Cell survival and apoptosis were quantified at 24-120 hours.
  • Antiproliferative and proapoptotic effects were observed in tumour cells but not in fibroblasts or non-malignant tissues. siRNA permutations and diverse overhangs influenced gene silencing efficacy. siRNA was quickly distributed to all organs and excreted via the kidney and liver.
  • Bcl-2 specific siRNA is a promising adjunctive treatment for pancreatic carcinoma.
  • [MeSH-major] Gene Silencing. Genes, bcl-2. Genetic Therapy / methods. Pancreatic Neoplasms / therapy. RNA, Small Interfering / therapeutic use. Transfection / methods
  • [MeSH-minor] 3' Untranslated Regions. 5' Untranslated Regions. Animals. Apoptosis / genetics. Blotting, Western. Cell Line, Tumor. Cells, Cultured. Humans. Kidney / metabolism. Liver / metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Polymerase Chain Reaction / methods. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):453-9 [14506747.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2003 Apr;13(2):83-105 [12804036.001]
  • [Cites] J Exp Ther Oncol. 2003 Jul-Aug;3(4):194-204 [14567290.001]
  • [Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]
  • [Cites] Acta Oncol. 2002;41(7-8):582-95 [14651201.001]
  • [Cites] RNA. 2004 Jan;10(1):12-8 [14681580.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:90-4 [14751826.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):936-48 [14769950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7 [14769924.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):326-30 [14758366.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):334-6 [2250705.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1645-51 [8194712.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Nature. 1995 Apr 20;374(6524):733-6 [7715730.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] Z Gastroenterol. 1997 May;35(5):319-26 [9265392.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Oncology. 1999;56(1):73-82 [9885381.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:7-30 [14531737.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):611-5 [10583267.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Trends Biochem Sci. 2000 May;25(5):241-6 [10782096.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1812-23 [10784621.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 10;1489(1):97-106 [10807000.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Lancet. 2000 Nov 18;356(9243):1728-33 [11095261.001]
  • [Cites] Breast Cancer Res Treat. 2000 Oct;63(3):199-212 [11110054.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):363-6 [11201747.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:403-19 [11264463.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Dig Dis. 2001;19(1):6-14 [11385246.001]
  • [Cites] Semin Cancer Biol. 2001 Jun;11(3):201-18 [11407945.001]
  • [Cites] J Pathol. 2001 Aug;194(4):444-50 [11523052.001]
  • [Cites] Mech Ageing Dev. 2001 Oct;122(15):1695-706 [11557274.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5466-74 [11571644.001]
  • [Cites] J Mol Med (Berl). 2001 Oct;79(10):587-93 [11692156.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):1991-6 [11972337.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):539-45 [12056703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7797-802 [12810955.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S81-8 [12867066.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):834-9 [12942087.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):38-9 [12097900.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 30;296(4):1000-4 [12200148.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Cell. 2002 Sep 6;110(5):563-74 [12230974.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):5196-201 [12391237.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] Mol Immunol. 2003 Jan;39(11):615-47 [12493639.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1566-9 [12393533.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2783-8 [12594341.001]
  • [Cites] J Mol Biol. 2003 Apr 4;327(4):761-6 [12654261.001]
  • [Cites] Eur J Biochem. 2003 Apr;270(8):1628-44 [12694176.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2705-16 [12771196.001]
  • [CommentIn] Gut. 2005 Sep;54(9):1215-6 [16099788.001]
  • (PMID = 16099798.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / 5' Untranslated Regions; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC1774673
  •  go-up   go-down


9. Lauro S, Trasatti L, Bria E, Gelibter A, Larosa G, Vecchione A: Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review. Anticancer Res; 2001 Jan-Feb;21(1B):563-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review.
  • Bronchoscopy showed an endobronchial mass; washing cytology was negative and histology findings suggested diagnosis of granular cell tumor (GCT), also called Abrikossoff's tumor.
  • After 3 weeks a new washing cytology test revealed the presence of small cell lung cancer (SCLC).
  • A CT-scan and chest radiography showed a 30% increase in the maximum diameter of the lesion, clinically defining the primary neoplasm as malignant.
  • The patient was referred to our institution and started chemotherapy with cisplatin and etoposide.
  • After 6 cycles of treatment, the CT scan showed complete, disappearance of the neoplasm and bronchoscopy examination showed no endobronchial lesion, defining the mucosal surface as normal.
  • We have reviewed and summarized the international literature with regard to bronchial localization of malignant granular cell tumor and its association with SCLC, therefore concluding that our case is the first malignant endobronchial GCT linked to SCLC.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoma, Small Cell / pathology. Granular Cell Tumor / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoalveolar Lavage Fluid / cytology. Bronchoscopy. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Middle Aged. Remission Induction. Smoking / adverse effects. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11299804.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Hadzismailović A, Pilav A: Evaluation of the preoperative stage and operative findings in patients with non-small cell lung cancer. Bosn J Basic Med Sci; 2007 Aug;7(3):239-44
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the preoperative stage and operative findings in patients with non-small cell lung cancer.
  • Lung cancer is responsible for 40% mortalities from malignant diseases in man and exhibits an extremely infiltrating way of growing.
  • According to its biological characteristics and response to treatments it may be divided in to small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC), which also includes other histological types.
  • Lung cancer treatment includes surgical treatment, chemotherapy, radiotherapy, the combination of the former three as well as symptomatic treatment.
  • In this study, we analyzed 125 patients with lung cancer, that were hospitalized at the Clinic for Thoracic Surgery in KCU Sarajevo.
  • The results of testing the significance of differences according to the cancer types in non small cell lung cancer were planocellular, adenocarcinoma, and macrocellular.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848150.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


11. Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS: Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer; 2009 Aug;65(2):242-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
  • BACKGROUND: Despite recent progress in palliative chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis is still poor.
  • Aside from multiple lines of chemotherapy, many patients need palliative procedures due to disease-related events.
  • METHODS: We evaluated 162 patients who were diagnosed with stage IIIB (with malignant effusion) or IV NSCLC at Seoul National University Hospital in 2005.
  • Forty-nine patients (30%) needed a palliative procedure at the time of diagnosis, and 59 patients (36%) required palliative procedure later during the course of their treatment.
  • The events requiring palliative procedures were thoracic events (malignant effusion or severe pneumonia requiring intensive care unit care not related to treatment) in 32 (30%), CNS events (brain metastasis or leptomeningeal metastasis) in 37 (34%), skeletal events (bone metastasis requiring radiation, spinal cord compression, hypercalcemia) in 29 (27%), and other events in 10 (9%).
  • The patients who had events at the time of diagnosis showed comparable overall survival to the patients without events at the time of diagnosis (14.6 months vs. 13.3 months, p=0.65).
  • The patients with later events during their course of treatment had a short median survival after the event requiring palliative procedures (median 2.7 months, 95% CI 2.19-3.21).
  • CONCLUSION: A considerable proportion of patients with advanced NSCLC receive palliative procedures apart from chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / complications. Lung Neoplasms / therapy. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147252.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Lucchi M, Viti A, Melfi F, Ambrogi M, Givigliano F, Dini P, Mussi A: IIIB-T4 non-small cell lung cancer: indications and results of surgical treatment. J Cardiovasc Surg (Torino); 2007 Jun;48(3):369-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IIIB-T4 non-small cell lung cancer: indications and results of surgical treatment.
  • AIM: T4 non-small cell lung cancer (NSCLC) is commonly considered a contraindication to surgery, indeed chemo-radiotherapy achieves a poor survival rate.
  • We have reviewed our experience with T4 NSCLC patients who underwent surgery with the aim of debating the indications and results of surgical treatment in this highly selected group of patients.
  • The tumors were classified T4 for the following reasons: intralobar satellite metastasis in 24 cases, direct mediastinum invasion in 18 cases, malignant pleural effusion in 7 cases, involvement of the superior vena cava in 4 cases, marginal invasion of the vertebral body in 3 cases, involvement of the carena in 3 cases and invasion of the left atrium in 1 case.
  • Thirteen patients had undergone neo-adjuvant chemotherapy while 39 underwent adjuvant therapies.
  • The prognosis was neither affected by the subtype of T4 tumor nor by the use of adjuvant therapies and/or neoadjuvant chemotherapy but only by the N status.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Patient Selection. Pneumonectomy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Male. Mediastinoscopy. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging / methods. Radiotherapy, Adjuvant. Risk Assessment. Risk Factors. Thoracic Surgery, Video-Assisted. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505443.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Hammerschmidt S, Pohlink C, Wirtz H, Rother T: [Alternating electric heart axis in a patient with small cell lung cancer]. Dtsch Med Wochenschr; 2004 Jan 2;129(1-2):19-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alternating electric heart axis in a patient with small cell lung cancer].
  • [Transliterated title] Alternierende elektrische Herzachse bei einem Patienten mit kleinzelligem Lungenkarzinom.
  • HISTORY AND ADMISSION FINDINGS: A 62-year-old man was admitted because of recurrent abdominal pain 18 months after small cell lung cancer (SCLC) had been diagnosed and remission achieved with chemotherapy and radiotherapy.
  • Symptomatic treatment brought improvement, but 16 hours after admission the patient complained of severe diffuse abdominal pain.
  • Heart sounds were decreased, while auscultation and percussion of the lung were unremarkable.
  • The needle aspirate of the pericardial fluid contained malignant cells.
  • DIAGNOSIS: These findings indicated malignant, hemodynamically significant pericardial effusion due to a recurrence of SCLC, with pronounced abdominal symptoms and advanced right heart failure.
  • TREATMENT AND COURSE: Pericardiocentesis brought about marked improvement.
  • 30 mg cisplatin was injected into the pericardial sac and chemotherapy resumed.
  • There was no tumor progression over the following 4 months when the pericardial effusion recurred, chemotherapy (4 cycles of carboplatin and etoposide) was restarted and another infusion of cisplatin undertaken.
  • CONCLUSION: This case report illustrates a not uncommon manifestation of lung cancer, malignant pericardial effusion, first becoming symptomatic as severe abdominal pain.
  • Characteristic changes in the chest radiogram and the ECG provided the diagnosis, confirmed histologically.
  • [MeSH-major] Carcinoma, Small Cell / complications. Heart Conduction System / physiopathology. Lung Neoplasms / complications. Neoplasm Recurrence, Local / complications. Pericardial Effusion / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Echocardiography. Electrocardiography. Etoposide / therapeutic use. Humans. Male. Middle Aged. Pericardiocentesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14703576.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Yoshida A, Edgar MA, Garcia J, Meyers PA, Morris CD, Panicek DM: Primary desmoplastic small round cell tumor of the femur. Skeletal Radiol; 2008 Sep;37(9):857-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary desmoplastic small round cell tumor of the femur.
  • Desmoplastic small round cell tumor (DSRCT) is a rare malignant neoplasm typically involving the abdominal cavity of a young male.
  • Despite chemotherapy and complete tumor excision, the patient developed progressive lung and bone metastases and died 3 years after initial presentation.
  • [MeSH-major] Diagnostic Imaging. Femoral Neoplasms / diagnosis. Sarcoma, Small Cell / diagnosis
  • [MeSH-minor] Biopsy. Child. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Hum Pathol. 2000 May;31(5):532-8 [10836292.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):454-9 [17325488.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23 (2):159-65 [9989842.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):167-71 [15642398.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3423-30 [12972518.001]
  • (PMID = 18470511.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Fischer BM, Mortensen J: The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration; 2006;73(3):267-76
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The future in diagnosis and staging of lung cancer: positron emission tomography.
  • Since its introduction in 1974, positron emission tomography (PET) has gained widespread use, especially in diagnosis and staging of lung cancer.
  • In this respect, (18)F-fluorodeoxyglucose (FDG) is by far the most used PET tracer exploiting the increased glucose uptake and metabolism in malignant cells.
  • A large number of studies have suggested that addition of FDG-PET to conventional workup can improve diagnosis and staging in patients with non-small cell lung cancer (NSCLC).
  • In 2001, the first integrated PET/computed tomography (CT) was installed, and since then, the use of this modality has expanded steadily, thereby decreasing examination time and overcoming the lack of anatomical details on PET.
  • Recently, PET and PET/CT have become increasingly integrated in therapy planning and evaluation: response evaluation during and after chemotherapy, restaging after neoadjuvant therapy, planning of radiotherapy and detection of recurrent disease are all examples of emerging indications for PET and PET/CT in managing patients with lung cancer.
  • [MeSH-major] Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / trends
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging / methods. Neoplasm Staging / trends. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16679747.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 105
  •  go-up   go-down


16. Spásová I, Petera J: Long-term clinical benefits of the low dose rate endobronchial irradiation of malignant airway obstructions. Neoplasma; 2001;48(3):234-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical benefits of the low dose rate endobronchial irradiation of malignant airway obstructions.
  • The purpose of our study was to evaluate the long-term clinical survival in patients with malignant airway compromise treated with endobronchial brachytherapy and to estimate possible influence of other factors on survival and to review complications of the therapy.
  • In a retrospective study 55 patients with malignant inoperable tracheobronchial lesions underwent 71 brachytherapy treatments with 137Cesium.
  • All except 4 patients received external radiation, 20 patients received chemotherapy, 37 patients received laser excision.
  • A relatively small number of complications of the endobronchial brachytherapy occured.
  • Significant bleeding was observed in 1 procedure and an inability to tolerate in 3 cases.
  • Bronchomediastinal fistula developed in 1 patient and tracheal stenosis in 1 patient.
  • The median survival from establishing the diagnosis was 510 days.
  • The median survival after the first brachytherapy treatment was 200 days.
  • We compared the survival in the subgroups of patients in relation to TNM status, chemotherapy, laser debulking brachytherapy device used.
  • The stage IIIA patients survived longer from diagnosis than IIIB patients but the difference was on the border of significance (p = 0.090).
  • In the evaluation of chemotherapy, more patients survived 12 months from the diagnosis (p = 0.045) when treated by chemotherapy comparing to the patients treated without chemotherapy.
  • In the Nd-YAG laser treatment, the patients treated by brachytherapy with the previous laser debulking survived significantly longer from the time of the first brachytherapy session (p = 0.005).
  • The LDR endobronchial brachytherapy is a well tolerated, safe and effective technique for palliation of malignant airway occlusions.
  • In our group of patients, the long-term survival was longer in IIIA stage comparing to the IIIB, in the group treated by the previous chemotherapy compared to the patients without chemotherapy and in the group with the Nd-YAG laser therapy, comparing to the group treated by the brachytherapy only.
  • [MeSH-major] Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Bronchial Neoplasms / mortality. Bronchial Neoplasms / pathology. Bronchial Neoplasms / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cesium Radioisotopes / therapeutic use. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Survival Analysis. Tracheal Neoplasms / mortality. Tracheal Neoplasms / pathology. Tracheal Neoplasms / radiotherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11583295.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cesium Radioisotopes
  •  go-up   go-down


17. Batura-Gabryel H, Foremska-Iciek J: Lung cancer in the elderly--increasing epidemiological problem of 21st century. Rocz Akad Med Bialymst; 2005;50 Suppl 1:152-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in the elderly--increasing epidemiological problem of 21st century.
  • Lung cancer is the second most common malignant neoplasm after prostate and breast cancers.
  • The elderly people over 65, are the most numerous population suffering from lung cancer.
  • More than 80% of all types of lung cancers make non-small cell lung cancer (NSCLC) and less than 20%--small cell lung cancer (SCLC).
  • The patients age is not a contradiction for the introducement of the treatment.
  • Surgical treatment is a method by choice at the early stages of NSCLC.
  • Single-agent chemotherapy seems to be benficial for the elderly with advanced NSCLC in good general condition, mainly due to less toxicity and satisfactory the survival rate.
  • Unfortunately, the effectivity of the therapy is occupied by its toxicity.
  • Still frequent occurrence and late diagnosis of lung cancer, high mortality, low efficiency of chemo- and radiotherapy causes the necessity of newer research for more effective screening methods, more effective and safer lung cancer treatment schemes for the elderly.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119652.001).
  • [Journal-full-title] Roczniki Akademii Medycznej w Białymstoku (1995)
  • [ISO-abbreviation] Rocz. Akad. Med. Bialymst.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Tomkowski WZ, Wiśniewska J, Szturmowicz M, Kuca P, Burakowski J, Kober J, Fijałkowska A: Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer; 2004 Jan;12(1):53-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.
  • GOALS: To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion.
  • The diagnosis of malignancy was based upon histological examination of samples from primary tumor.
  • The majority of patients suffered from a neoplasm localized in the thorax (41 out of 46 patients; 89%).
  • Malignant etiology of pericardial fluid was confirmed by cytological examination, histology being obtained by VATS pericardial biopsy or by echocardiography (ECG).
  • Treatment was considered as successful when recurrence of symptoms of large pericardial effusion was not observed in ECG and other interventions directed to the pericardium were not required.
  • Efficacy of investigated treatment was assessed also in the group of patients with survival longer than 30 days.
  • Safety of treatment was assessed in the whole group of patients.
  • Positive effect of intrapericardial treatment with cisplatin was achieved in 43 out of 46 patients (93.5%) in the entire investigated group and in 35 out of 38 patients (92%) who survived more than 30 days.
  • In the subgroup of patients with non-small cell lung cancer (NSCLC) and survival longer than 30 days, high efficacy was documented (29 out of 31 cases; 93.5%).
  • Median survival time in the group of 38 patients who survived more than 30 days was 102.5 days.
  • CONCLUSIONS: Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cardiac Tamponade / etiology. Cisplatin / administration & dosage. Lung Neoplasms / surgery. Pericardial Effusion / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / surgery. Drainage. Female. Humans. Injections, Intralesional. Male. Middle Aged. Pericardiocentesis / adverse effects. Pericardium. Recurrence. Survival Analysis. Thoracic Surgery, Video-Assisted / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 1997 Mar;16(2-3):215-22 [9152952.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):59-64 [8007081.001]
  • [Cites] Chest. 1999 Aug;116(2):275-6 [10453849.001]
  • [Cites] Monaldi Arch Chest Dis. 1995 Apr;50(2):86-8 [7613552.001]
  • [Cites] Oncology. 1994 Nov-Dec;51(6):507-9 [7526307.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3141-7 [8955660.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):437-42 [1617593.001]
  • [Cites] Am J Med. 1998 Aug;105(2):106-9 [9727816.001]
  • [Cites] Mayo Clin Proc. 1998 Jul;73(7):647-52 [9663193.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Chest. 1996 Jun;109(6):1452-4 [8769492.001]
  • [Cites] Herz. 2000 Dec;25(8):787-93 [11200128.001]
  • [Cites] Support Care Cancer. 1997 Jan;5(1):64-6 [9010992.001]
  • [Cites] Ann Thorac Surg. 1997 Nov;64(5):1422-7; discussion 1427-8 [9386714.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2371-6 [9667253.001]
  • [Cites] Chest. 1998 Apr;113(4):861-6 [9554616.001]
  • [Cites] Mayo Clin Proc. 2000 Mar;75(3):248-53 [10725950.001]
  • [Cites] Monaldi Arch Chest Dis. 1997 Jun;52(3):221-4 [9270245.001]
  • [Cites] Am J Cardiol. 1987 Nov 15;60(14):1161-6 [2446487.001]
  • [Cites] Circulation. 1962 Aug;26:228-41 [14037856.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1993 Apr;7(2):178-83 [8477023.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] JAMA. 1987 Feb 27;257(8):1088-92 [3806903.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Eur Heart J. 2002 Oct;23(20):1625-31 [12323163.001]
  • (PMID = 14505155.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H, Go el U: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol; 2000 Nov;11(11):1451-62
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.
  • BACKGROUND: An update of results from the High Risk Protocol of the Meta-EICESS Study, conducted at the Pediatric Stem-Cell Transplant Centers of Düsseldorf and Vienna.
  • In order to evaluate a possible therapeutic benefit after allogeneic SCT in patients with advanced Ewing tumors (AET), we compared outcome after autologous and allogeneic stem-cell transplantation (SCT).
  • All patients underwent remission induction chemotherapy and local treatment before myeloablative therapy.
  • We analyzed the following risk factors, that could possibly influence the event-free survival (EFS): number of involved bones, degree of remission at time of SCT, type of graft, indication for SCT, bone marrow infiltration, bone with concomitant lung disease, age at time of diagnosis, pelvic involvement, involved compartment radiation, histopathological diagnosis.
  • Eighteen of thirty-six patients suffered relapse or died of disease, nine of thirty-six died of treatment related toxicity (DOC).
  • Age > or = 17 years at initial diagnosis (P < 0.005) significantly deteriorated outcome.
  • According to the type of graft, EFS was 0.25 +/- 0.08 after autologous and 0.20 +/- 0.13 after allogeneic SCT.
  • CONCLUSIONS: Because of the rather short observation period. secondary malignant neoplasms (SMN) may complicate the future clinical course of some of our patients who are currently viewed as event-free survivors.
  • The patient group was to small to analyze for a possible graft-versus-tumor effect.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142486.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2
  • [Number-of-references] 56
  •  go-up   go-down


20. Peled N, Flex D, Raviv Y, Fox BD, Shitrit D, Refaeli Y, Sauté M, Amital A, Kramer MR: The role of routine bronchoscopy for early detection of bronchial stump recurrence of lung cancer: 1 year post-surgery. Lung Cancer; 2009 Sep;65(3):319-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of routine bronchoscopy for early detection of bronchial stump recurrence of lung cancer: 1 year post-surgery.
  • This study focuses on early detection of stump recurrence by a routine bronchoscopy.
  • Four of the nine polyps were malignant.
  • Malignant stump recurrence was observed in four cases, all had a stump polyp.
  • For stump recurrence, one patient underwent completion pneumonectomy and has no evidence for disease (32.2 months), two patients were treated by chemotherapy and one patient died from pneumonia before therapy.
  • [MeSH-major] Bronchoscopy. Carcinoma, Non-Small-Cell Lung / diagnosis. Early Diagnosis. Lung Neoplasms / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy. Polyps. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144443.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Choi HJ, Park IA: Fine needle aspiration cytology of metastatic choriocarcinoma presenting as a breast lump. A case report. Acta Cytol; 2004 Jan-Feb;48(1):91-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: While choriocarcinoma is a rapidly invasive, widely metastasizing malignancy, it responds well to chemotherapy, so it is important to obtain an early diagnosis.
  • Chest computed tomography revealed multiple nodules in both lung fields.
  • The breast mass was clinically suspected to be a metastatic lung cancer.
  • FNAC of the breast showed a malignant tumor that had been misdiagnosed as a metastatic non-small cell carcinoma of the lung.
  • CONCLUSION: The cytologic features of choriocarcinoma are quite characteristic, with side-by-side, malignant, mononucleated cells and multinucleated giant cells corresponding to cytotrophoblasts and syncytiotrophoblasts, respectively.
  • [MeSH-major] Breast Neoplasms / secondary. Choriocarcinoma / secondary. Lung Neoplasms / secondary. Nose Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cell Nucleus / pathology. Chorionic Gonadotropin, beta Subunit, Human / blood. Cough / etiology. Cough / pathology. Diagnosis, Differential. Epistaxis / etiology. Epistaxis / pathology. Female. Giant Cells / pathology. Hemoptysis / etiology. Hemoptysis / pathology. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14969189.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


22. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • We reported eight cases of stage IV small cell neuroendocrine carcinoma of the head and neck, all in men with a mean onset age of 62 years (range: 45 to 80 years).
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Five patients died of distant metastasis to the brain, bone, lung, liver, or skin within 12 months.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


23. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol; 2003 Jul;10(6):697-704
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary carcinoid tumors are neuroendocrine malignant tumors that make up 1% to 2% of all lung tumors.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
  • The diagnosis is usually established by flexible bronchoscopy and biopsy, although occasionally this can result in severe hemorrhage.
  • Immunoscintigraphy by somatostatin analogs can also be useful in diagnosis.
  • The treatment of choice is surgical resection, and prognosis is relatively good in TC, although it is worse in AC.
  • The role of radiotherapy and chemotherapy as part of multimodality treatment or palliation is still debated.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms
  • [MeSH-minor] Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Fever / etiology. Hemoptysis / etiology. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radioimmunodetection. Radiotherapy, Adjuvant. Respiratory Sounds / etiology. Somatostatin

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839856.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


24. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC: Pemetrexed-induced pneumonitis: a case report. Clin Lung Cancer; 2009 Sep;10(5):364-6
Hazardous Substances Data Bank. CIPROFLOXACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Hypersensitivity / diagnosis. Lung / drug effects. Lung Neoplasms / drug therapy. Pneumonia / diagnosis. Solitary Pulmonary Nodule / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Aged. Anti-Infective Agents / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Ciprofloxacin / administration & dosage. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Therapy, Combination. Dyspnea. Erythema. Glutamates / administration & dosage. Glutamates / adverse effects. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Pemetrexed. Pulmonary Fibrosis. Recovery of Function

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19808196.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5E8K9I0O4U / Ciprofloxacin; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Only small numbers of bona fide examples exist in the world literature; cases arising primarily at extranodal sites are not well described and often seem to go unrecognized.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement